Abstract
Background:
Ovarian transposition is recommended for preservation of ovarian function to prevent the sequelae of early menopause and to retain fertility. Potential postoperative risks of the procedure—including torsion, pain, bleeding, cyst formation, and malignant neoplasms—have been reported with low incidence. The aim of this report is to demonstrate the occurrence of an ovarian pathology in a patient who underwent ovarian transposition even after undergoing chemotherapy and radical surgery for cervical cancer.
Case:
A 44-year-old, gravida 3, para 2, woman presented with an ovarian cystic mass after neoadjuvant chemotherapy, radical hysterectomy with bilateral pelvic node dissection, and ovarian transposition for early stage cervical cancer.
Results:
The patient underwent a laparoscopic right cystectomy. The right ovary was enlarged to a 6-cm, multiloculated cystic mass with a thin capsule and mucinous fluid within it. The histopathology result confirmed that the mass was a mucinous cystadenoma. The patient has been free of disease for more than 10 years.
Conclusions:
Although ovarian transposition aids in preventing ovarian failure that can lead to symptoms of early menopause, there is still the possibility of an ovarian neoplasm arising in the remaining ovaries. Consistent follow-up is recommended to assess patients who undergo ovarian transposition. (J GYNECOL SURG 36:217)
Get full access to this article
View all access options for this article.